DP3: Corporate Governance Report (first 06 months)
DP3: Audited report on the use of proceeds collected from the share issuance to increase the charter capital from VND 68 billion up to VND 86 billion
With risks from interruption of the medical ingredient supply chain and losses in the hospital channel, the Vietnamese pharma industry experienced a topsy-turvy first half of 2021, with potential growth set to focus on mergers and acquisitions.